SDICSI 2026 年 1 月 29 日 卓正医疗 (2677.HK) 卓正医疗 IPO 点评 公司概览 卓正医疗是中国知名的私立医疗服务机构，核心聚焦中高端医疗服务市场。截至 2026 年 1 月 20 日，公司在国内布局并经营 19 家医疗服务机构，含 17 家诊所、 2 家医院；海外业务方面，在新加坡设有 4 家全科诊所，在马来西亚运营 1 家全 科诊所。根据弗若斯特沙利文的数据，在私立中高端医疗服务分部中，按 2024 年收入计，公司是中国第三大私立中高端医疗服务机构，市场份额达 2.0%。 财务方面，2022 年、2023 年、2024 年以及截至 2025 年 8 月 31 日，公司分别 实现收入 4.7 亿元、6.9 亿元、9.6 亿元及 7.0 亿元；同期对应净利润分别为-2.2 亿元、-3.5 亿元、8,023 万元及 8,321 万元。 行业状况及前景 根据弗若斯特沙利文的数据，中国私立中高端医疗服务市场的总收入由 2020 年 的 1,930 亿元增长到 2024 年的 4,263 亿元，复合年增长率为 21.9%，预计 2024 年至 2029 年将以 14.3%的复合年增长率增长 ...

公司引入Health Vision Hong Kong Limited、广州金域医学检验集团股份有限公司、明略科技、Galaxy Dynasty Limited等基石投资者，将以发售价共认购数量下限约134.95万股可购买发售的股份。 卓正医疗(02677.HK)发布公告，公司拟全球发售475.00万股股份，其中香港发售股份47.50万股，国际发 售股份427.50万股，另有71.25万股超额配股权。招股日期为1月29日至2月3日，最高发售价66.60港元， 每手买卖单位50股，入场费约3363.58港元。 全球发售预计募资总额为2.95亿港元，募资净额2.19亿港元，募资用途为用于通过打造一个医疗人工智 能应用的专业人才库、与领先的科研机构及公司开展战略合作及外部采购；用于升级现有医疗服务机构 及设立新医疗服务机构；用于在适当机会出现时收购一线城市及新一线城市中业绩良好的医疗服务机 构；用作营运资金及其他一般公司用途。 公司2022年度、2023年度、2024年度截至12月31日止，净利润分别为-2.15亿元、-3.51亿元、8380.50万 元，同比变动幅度为14.13%、-62.73%、123.90%。 ...

卓正医疗（02677）于2026年1月29日至2026年2月3日招股，该公司拟全球发售475万股，其中香港发售 占10%，国际发售占90%，另有15%超额配股权，发售价每股57.7-66.6港元。每手50股，预期股份将于 2026年2月6日在联交所开始买卖。 该公司是中国的私立医疗服务机构，战略重点是服务中高端医疗服务市场，目标群体是具有较强购买力 及偏好更个性化护理的大众富裕人群。 公司已与Health Vision、金域医学检验、明略科技、Galaxy Dynasty订立基石投资协议，基石投资者已同 意在若干条件规限下按发售价认购或促使其指定实体认购总额1164万美元可购入有关数目的发售股份 （向下约整至最接近每手50股的完整买卖单位）。基石投资者将认购的发售股份数目须视乎最终发售价 而定。 该公司是中国的私立医疗服务机构，战略重点是服务中高端医疗服务市场，目标群体是具有较强购买力 及偏好更个性化护理的大众富裕人群。 公司已与Health Vision、金域医学检验、明略科技、Galaxy Dynasty订立基石投资协议，基石投资者已同 意在若干条件规限下按发售价认购或促使其指定实体认购总额1164万美元 ...

Core Viewpoint - 卓正医疗 is planning a global offering of 4.75 million shares, targeting the high-end medical service market in China, with a focus on affluent consumers seeking personalized care [1][2]. Company Overview - 卓正医疗 is a private medical service provider in China, emphasizing high-end medical services for affluent individuals with a disposable income exceeding RMB 200,000 [1]. - The company is the third-largest private high-end medical service provider in China, holding a market share of 2.0% in the private high-end medical service sector [2]. Market Insights - The total revenue of China's private high-end medical service market is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion by 2024, with a compound annual growth rate (CAGR) of 21.9% [2]. - By 2029, the market is expected to reach RMB 831.4 billion, continuing to grow at a CAGR of 14.3% from 2024 to 2029 [2]. Fundraising and Use of Proceeds - The company has entered into cornerstone investment agreements, with cornerstone investors agreeing to subscribe for shares totaling approximately HKD 90.79 million [3]. - Assuming a mid-range offer price of HKD 62.15 per share, the company estimates net proceeds of approximately HKD 219.1 million from the global offering [4]. - The intended use of proceeds includes 35% for developing a talent pool for medical AI applications, 30% for upgrading existing facilities and establishing new ones, 25% for acquiring well-performing medical institutions, and 10% for working capital [4].

Group 1: Company Overview - The company, 卓正医疗, is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market targeting affluent individuals with a disposable income exceeding RMB 200,000 per year [2] - Established in 2012, the company operates 19 medical service institutions across major Chinese cities and has additional clinics in Singapore and Malaysia [3] - The company aims to expand its network through organic growth and strategic acquisitions, particularly in new first-tier cities [3] Group 2: Market Position and Growth - In 2024, private mid-to-high-end medical service institutions are expected to account for approximately 66.5% of the total revenue in China's mid-to-high-end medical service market, representing about 5.6% of the overall healthcare market [2] - The total revenue of China's private mid-to-high-end medical service market is projected to grow from RMB 193 billion in 2020 to RMB 426.3 billion in 2024, with a compound annual growth rate (CAGR) of 21.9% [2] - By 2029, the market is expected to reach RMB 831.4 billion, continuing to grow at a CAGR of 14.3% from 2024 to 2029 [2] Group 3: IPO Details - The company plans to offer 4.75 million shares globally, with 10% allocated for Hong Kong and 90% for international sales, and an additional 15% over-allotment option [1] - The expected price range for the shares is HKD 57.7 to 66.6, with trading anticipated to commence on February 6, 2026 [1] - The estimated net proceeds from the global offering are approximately HKD 219 million, which will be allocated for various strategic initiatives, including AI application development and upgrading existing medical facilities [4]

智通财经APP讯，卓正医疗(02677)于2026年1月29日至2026年2月3日招股，该公司拟全球发售475万股， 其中香港发售占10%，国际发售占90%，另有15%超额配股权，发售价每股57.7-66.6港元。每手50股， 预期股份将于2026年2月6日在联交所开始买卖。 该公司是中国的私立医疗服务机构，战略重点是服务中高端医疗服务市场，目标群体是具有较强购买力 及偏好更个性化护理的大众富裕人群。大众富裕人群是指人均年可支配收入超过人民币20万元的人口群 体。中国的医疗服务市场可大致分为平价医疗服务市场及中高端医疗服务市场。中高端医疗服务是指综 合性定制服务，强调患者体验及服务质量，并可进一步分为公立中高端医疗服务及私立中高端医疗服 务。于 2024年，私立中高端医疗服务机构占中国中高端医疗服务市场总收入约66.5%及占中国医疗服务 行业总收入约5.6%。根据弗若斯特沙利文的资料，中国私立中高端医疗服务市场的总收入由2020年的 人民币1,930亿元增长到2024年的人民币4,263亿元，复合年增长率为21.9%，预计2024年至2029年将继 续以14.3%的复合年增长率增长，到2029年达到人民币8, ...

Core Viewpoint - The integration of artificial intelligence (AI) in healthcare is seen as a powerful tool to assist doctors, but it cannot replace the human aspects of medicine, such as doctor-patient communication and emotional support [2][3][4][5]. Group 1: Role of Artificial Intelligence in Healthcare - AI technology is rapidly evolving and provides significant advantages in diagnosing and treating diseases, acting as a "super brain" that surpasses individual doctors in memory, reasoning, and computational abilities [2]. - AI can enhance diagnostic accuracy and efficiency, allowing doctors to focus more on patient interactions, which is essential for fostering a harmonious doctor-patient relationship [2][3]. Group 2: Human Element in Medicine - Despite advancements in AI, the complexity and unpredictability of human life mean that AI cannot fully replace doctors, who must remain the primary decision-makers in patient care [3][4]. - The emotional connection between doctors and patients is irreplaceable, as effective medical care involves understanding both the physiological and psychological dimensions of illness [4][5]. - Historical insights from medical experts emphasize the importance of maintaining personal interactions in healthcare, warning against over-reliance on technology for diagnosis and treatment [3][5]. Group 3: Importance of Humanistic Care - Humanistic care is a critical value in medicine, where emotional exchanges between doctors and patients cannot be substituted by technology [5]. - The essence of medical practice lies in the compassion and warmth that doctors provide, which is vital for building trust and rapport with patients [4][5]. - The future of medicine is envisioned as a collaboration between humans and machines, where the core values of empathy and care remain central to the practice [3][5].

Core Insights - OpenEvidence, a medical AI startup, has completed a $250 million Series D funding round, achieving a valuation of $12 billion [1] - The funding round was led by Thrive Capital and DST Global, with the total financing amount nearing $700 million [1] - OpenEvidence's AI-driven medical search engine supported approximately 18 million clinical consultations from certified doctors in the U.S. last December, compared to about 3 million consultations per month a year earlier [1]

Core Insights - The signing of the ecological cooperation agreement marks a significant step towards the implementation of the National AI Application Pilot Base in the medical field, focusing on data production, model development, and market promotion [1] Group 1: Cooperation Mechanism - The ecological cooperation agreement outlines the collaboration mechanisms, rights and responsibilities, and performance evaluation indicators among participants in the healthcare AI sector [1] - Key aspects such as data rights ownership, intellectual property sharing, and profit distribution from results have been clearly defined to ensure sustainable cooperation among medical institutions, AI companies, and base operators [1] Group 2: Collaborative Initiatives - Beijing Tongren Hospital and Beijing Medical Health Large Model Co., Ltd. signed a cooperation agreement focusing on ophthalmology, establishing a joint innovation laboratory and application promotion center [1] - The collaboration aims to create a high-quality dataset for ophthalmology AI products, facilitating clinical transformation and promoting applications across various healthcare institutions [1] Group 3: Future Directions - The city plans to use demonstration projects as benchmarks to drive the integration of medical AI technology innovation with industry applications [1] - This initiative aims to contribute valuable experience and momentum for the collaborative innovation development of the national medical AI industry [1]

Group 1 - The signing of the ecological cooperation agreement marks a significant step towards the large-scale implementation of the National AI Application Pilot Base in the medical field, focusing on data production, model development, and market promotion [1] - The initiative aims to address long-standing challenges in data rights, intellectual property, and market promotion mechanisms that have hindered cooperation between medical enterprises and AI companies [1] - The ecological cooperation agreement establishes a stable institutional framework for sustainable collaboration among medical institutions, AI companies, and base operating enterprises, clarifying cooperation mechanisms, rights and responsibilities, and performance evaluation indicators [1] Group 2 - The Capital Medical University Affiliated Beijing Tongren Hospital and Beijing Medical Health Large Model Co., Ltd. signed an ecological cooperation agreement focusing on ophthalmology, establishing a joint innovation laboratory and application promotion center [2] - The collaboration aims to create a high-quality dataset for ophthalmology, facilitating the clinical transformation of AI products and promoting their application across various medical institutions and community health service centers [2] - Beijing plans to use demonstration projects as benchmarks to drive the deep integration of medical AI technology innovation and industry application, contributing to the collaborative innovation development of the national medical AI industry [2]